AMG-517

AMG-517
AMG-517
AMG-517 structure.png
식별자
  • N-{6-[4-(트리플루오로메틸)페닐]피리미딘-4-일}옥시-1, 3-벤조티아졸-2-일)아세트아미드
CAS 번호
PubChem CID
켐스파이더
유니
첸블
CompTox 대시보드 (EPA )
화학 및 물리 데이터
공식C20H13F3N4O2S
몰 질량430.41 g/g−1/표준
3D 모델(JSmol)
  • CC(=O)NC1=NC2=C(C=CC=C2S1)OC3=NC=NC(=C3)C4=CC=C(C=C4)C(F)(F)f
  • InChI=1S/C20H13F3N4O2S/c1-11(28)26-19-27-18-15(3-2-4-16)30-19)29-17-14(24-10-25-17)12-5-7-13(8-6-12-202/22)
  • 키: YUTIXVXZQIQWGY-UHFFFAOYSA-N

AMG-517TRPV1 이온 [1][2]채널의 강력하고 선택적인 차단제 역할을 하는 약물입니다.만성 통증에 대한 잠재적 치료제로 개발되었지만, 동물 연구의 효과적인 진통제였지만 부작용으로 온열증 발생과 수용성 저하로 인해 1단계 임상시험에서 제외되었다.TRPV1 채널의 기능과 통증 및 염증에서의 역할에 대한 과학적 연구에 여전히 사용되며,[3][4][5][6][7] 특성을 개선한 몇 가지 새로운 유사체 설계를 위한 템플릿으로 사용되어 왔다.

「 」를 참조해 주세요.

레퍼런스

  1. ^ Doherty EM, Fotsch C, Bannon AW, Bo Y, Chen N, Dominguez C, et al. (July 2007). "Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate". Journal of Medicinal Chemistry. 50 (15): 3515–27. doi:10.1021/jm070190p. PMID 17585750.
  2. ^ Wang HL, Katon J, Balan C, Bannon AW, Bernard C, Doherty EM, et al. (July 2007). "Novel vanilloid receptor-1 antagonists: 3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties". Journal of Medicinal Chemistry. 50 (15): 3528–39. doi:10.1021/jm070191h. PMID 17585751.
  3. ^ Wang X, Chakrabarti PP, Ognyanov VI, Pettus LH, Tamir R, Tan H, et al. (December 2007). "Trisubstituted pyrimidines as transient receptor potential vanilloid 1 (TRPV1) antagonists with improved solubility". Bioorganic & Medicinal Chemistry Letters. 17 (23): 6539–45. doi:10.1016/j.bmcl.2007.09.080. PMID 17937985.
  4. ^ Gavva NR, Treanor JJ, Garami A, Fang L, Surapaneni S, Akrami A, Alvarez F, Bak A, Darling M, Gore A, Jang GR, Kesslak JP, Ni L, Norman MH, Palluconi G, Rose MJ, Salfi M, Tan E, Romanovsky AA, Banfield C, Davar G (May 2008). "Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans". Pain. 136 (1–2): 202–10. doi:10.1016/j.pain.2008.01.024. PMID 18337008. S2CID 11557845.
  5. ^ Gavva NR (November 2008). "Body-temperature maintenance as the predominant function of the vanilloid receptor TRPV1". Trends in Pharmacological Sciences. 29 (11): 550–7. doi:10.1016/j.tips.2008.08.003. PMID 18805596.
  6. ^ Garami A, Ibrahim M, Gilbraith K, Khanna R, Pakai E, Miko A, et al. (November 2017). "Transient Receptor Potential Vanilloid 1 Antagonists Prevent Anesthesia-induced Hypothermia and Decrease Postincisional Opioid Dose Requirements in Rodents". Anesthesiology. 127 (5): 813–823. doi:10.1097/ALN.0000000000001812. PMID 28806222. S2CID 38802079.
  7. ^ Tsagareli MG, Nozadze I, Tsiklauri N, Carstens MI, Gurtskaia G, Carstens E (November 2020). "Thermal Hyperalgesia and Mechanical Allodynia Elicited by Histamine and Non-histaminergic Itch Mediators: Respective Involvement of TRPV1 and TRPA1". Neuroscience. 449: 35–45. doi:10.1016/j.neuroscience.2020.09.048. PMC 8219216. PMID 33010342.